VIZhyal 0.4% contains one of the highest available concentrations of cross-linked sodium hyaluronate Put one drop in the affected eye(s) as directed by your doctor. Blink a few times so that the drop spreads over the eye. If you are not sure how to administer your medicine, ask your doctor, pharmacist or nurse. Composition: Sodium hyaluronate 0.1% sodium phosphate monobasic monohydrate, sodium phosphate dibasic dodecahydrate, sodium chloride, water for injection. The patient should instill one drop in the affected eye(s) as directed by the physician. The patient should blink a few times so that the drop spreads over their eye should be instructed to seek advice from their doctor, pharmacist or nurse if they are not sure how to administer their medicine.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart. For patients with moderate episodic or chronic discomfort with or without environmental stress. Episodic visual symptoms which are annoying and/or activity-limiting. If blepharitis or evaporative dry eye: use Systane Balance (propylene glycol 0.6%) or Optive Plus (carboxymethylcellulose 0.5%, glycerine 1%, castor oil), 10ml, 6m expiry. Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the active substance to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials with dorzolamide, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors. When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily.VIZcellose 1.0% is a sterile, ophthalmic solution that protects and moisturizes the ocular surface of the eye. VIZcellose 1.0% relieves the symptoms of dry eyes such as burning, itching and foreign body sensation. Acting as a lubricant, VIZcellose drops provide relief from dry eye conditions, including those associated with the use of PC, infrequent blinking, certain medical treatments, atmospheric pollution, dry atmospheres (e.g., air conditioning), and ophthalmic stress due to the use of eye lenses. VIZcellose 1.0% can be suggested in the case of mild dry eye syndrome, when immediate protective action and lasting relief is required. After all doses have been used there will be some Vizidor left in the bottle. The patient should not be concerned since an extra amount of Vizidor has been added and the patient will get the full amount of Vizidor that their doctor has prescribed. Using the excess medicine remaining in the bottle after the patient has completed the course of treatment should not be attempted. Composition: 0.5% carmellose sodium (carboxymethyl cellulose), boric acid, sodium tetraborate decahydrate, sodium chloride, water for injection.

Patients generally have mild discomfort or episodic discomfort under environmental stress. No visual symptoms or episodic mild fatigue. For patients who are allergic to lanolin, alternative lanolin-free eye ointment can be obtained from specialist. In a multiple-dose, double-masked, active treatment (dorzolamide multidose) controlled, two period crossover multiclinic study, in 152 patients with elevated baseline intraocular pressure (baseline IOP ≥22 mmHg) in one or both eyes, dorzolamide preservative-free had an IOP-lowering effect equivalent to that of dorzolamide multidose. The safety profile of dorzolamide preservative-free was similar to dorzolamide multidose. When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, active substance and metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free active substance in plasma are maintained. The parent active substance forms a single N-desethyl metabolite that inhibits CA-II less potently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs non-linearly, resulting in a rapid decline of active substance concentration initially, followed by a slower elimination phase with a half-life of about four months. The following side effects have been reported with dorzolamide preservative free either during clinical trials or during post-marketing experience:Composition: Sodium hyaluronate cross polymer aqueous solution (of which sodium hyaluronate cross polymer 0,4%), Trometamol, Hydrochloric acid 2N, Sodium chloride, water for injection. If you are using Vizidor with another eye drop, the drops should be instilled at least 10 minutes apart. Composition: Hyaluronic acid sodium salt (high molecular weight), Hyaluronic acid sodium salt (low molecular weight) L-Glycine, Vitamin E, TPGS, Extract of Centella Asiatica (L.) Urban (titrated in asiaticoside 3%), Polyvinylpyrrolidone, D-Mannitol, Sodium phosphate monobasic monohydrate, Sodium Phosphate dibasic dodecahydrate, Sodium Chloride, water for injection. If you develop allergic reactions including hives, swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing, you should stop using this medicine and seek immediate medical advice.

Hylo-Tear*** 0.1% or Hylo-Forte*** 0.2%. 300 drops metered dose bottle, 6m expiry. Can prescribe ComplEYE aid.Recommend overnight treatment with a paraffin-based PF eye ointment: Xailin Night or Hylo-Night (formerly known as VitA-POS) or HydraMed Night Eye Ointments, 5g. Systane Balance (propylene glycol 0.6%) or Optive Plus (carboxymethylcellulose 0.5%, glycerine 1%, castor oil). 10ml, 6m expiry, contains preservative. Dorzolamide contains a sulphonamido group, which also occurs in sulphonamides and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulphonamides may occur with topical administration, including severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation. The following adverse effects have been reported either during clinical trials or during post-marketing experience with dorzolamide: